Chiesi grants Curosurf license, invests in Cornerstone
Italy's Chiesi Farmaceutici SPA has granted spec pharma Cornerstone Therapeutics an exclusive US license to sell its porcine-derived lung surfactant Curosurf (poractant alfa) for the next ten years (renewable thereafter automatically in one-year increments). Cornerstone also obtained the first right of offer on any drugs or technologies--most likely in the respiratory field, including Phase I synthetic surfactant Nymusa for sleep apnea--which Chiesi plans to launch in the US.
- Specialty Pharmaceuticals
- Includes Equity
- Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.